Home

Clinical Trials

Memorial Sloan Kettering clinical trials are now available for Hartford HealthCare Cancer Institute patients.

As part of the Hartford HealthCare Cancer Institute’s pioneering membership in the Memorial Sloan Kettering (MSK) Cancer Alliance, an increasing number of MSK’s leading-edge cancer clinical trials and protocols are now being offered to cancer patients who receive care within the Institute.

That means promising and potentially groundbreaking advances in cancer research and treatment are being made available to patients without requiring them to go to New York City, where MSK is located and where previously patients had to travel to gain access to MSK’s world-renowned bank of trials and protocols.

The rollout of MSK clinical trials to patients within Hartford HealthCare is a cornerstone the Institute’s membership in the Alliance. As of July 2016, the Institute had made MSK-originated clinical trials and research protocols available to patients who are being cared at any of the five cancer centers that make up the Cancer Institute – Hartford Hospital, Backus Hospital, Windham Hospital, The Hospital of Central Connecticut and MidState Medical Center. Additional trials and studies are expected to be opened to patients over the next several months.

The MSK trials are being made available in addition to a wide array of promising trials and research protocols now being offered to patients as part of the Institute’s Cancer Clinical Research Office, which are conducted by physicians and research specialists at the various cancer centers within the Institute.

“Our goal is to add to our existing portfolio of studies and to offer a comprehensive array of clinical trials for patients with common and uncommon cancers treated at the Hartford HealthCare Cancer Institute,” said Ellen Dornelas, PhD, Director of the Cancer Clinical Research Office.

What is the "Cancer Moon Shot"?

Have you heard of the cancer moonshot? "We've been told by the federal government that the goal is to do what you are doing anyway, but do it a lot faster," says Dr. Peter Wu, Senior VP, Hartford HealthCare & Physician-in-Chief, Hartford HealthCare Cancer Institute. "So, instead of taking ten years to accomplish something, figure out how to do it in five."


  • Lung Cancer EA5142

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial that studies how well Nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.

  • Lung Cancer E4512

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) that studies how well Crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • Lung Cancer Alchemist A081105

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) trial that studies how well Erlotinib Hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

  • Lung Cancer Alchemist A151216

    April 27, 2017

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been, or will be removed by surgery.

  • Melanoma EA6134

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) which studies how well initial treatment with Ipilimumab and Nivolumab followed by Dabrafenib and Trametinib works and compares it to initial treatment with Dabrafenib and Trametinib followed by Ipilimumab and Nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery.

  • Melanoma ECOG3612

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) which studies how well Ipilimumab with or without Bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.

  • Myeloma CC-4047-MM-007

    April 27, 2017

    The purpose of this study is to compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of Pomalidomide, Bortezomib and Dexamethasone is compared to the combination of Bortezomib and Dexamethasone.

  • Myeloma E3A06

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial which studies how well Lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering, an early precursor to blood cancer) multiple myeloma.

  • Lymphoma B3281006

    April 27, 2017

    This study will compare the safety and effectiveness of PF-05280586 versus Rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.

  • Hematological CC-486-AML-001

    April 26, 2017

    This study will enroll approximately 460 subjects, aged 55 or older, with a diagnosis of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved first complete remission.

  • Gastrointestinal Cancer 3475-181

    April 26, 2017

    This study focuses on treating patients who have undergone surgery for head and neck cancer that has spread to nearby tissues or organs.

  • Head/Neck Cancer 0920

    April 26, 2017

    This study focuses on treating patients who have undergone surgery for head and neck cancer that has spread to nearby tissues or organs.

  • Gynecologic Cancer 286B

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial studies how well Paclitaxel, Carboplatin, and Metformin Hydrochloride works and compares it to Paclitaxel, Carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back.

  • Gynecologic Cancer NRG-005

    April 26, 2017

    This trial studies how well Cediranib Maleate and Olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

  • Gynecologic Cancer NRG-004

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial that studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Phase III trials are new treatments that have worked well in a small number of patients with a disease.

  • Gynecologic Cancer GOG 281

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial that studies how well Trametinib works and compares it to standard treatment with either Letrozole, Tamoxifen citrate, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, or Topotecan hydrochloride in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to other parts of the body.

  • Gynecologic Cancer ET743-OVC-3006

    April 26, 2017

    The purpose of this study is to assess the efficacy and safety of Trabectedin+DOXIL as a third-line chemotherapy regimen in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

  • Gynecologic Cancer 3005/ABBVIE M13-694

    April 26, 2017

    The focus of this study is to evaluate the efficacy, safety, and tolerability of Veliparib in women with previously untreated, Stage III or IV (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer), high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  • Gynecologic Cancer 264

    April 26, 2017

    This trial studies Paclitaxel and Carboplatin to see how well they work compared with Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in treating patients with sex cord-ovarian stromal tumors (gastrointestinal) that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent).

  • Gynecologic Cancer 274

    April 26, 2017

    This trial studies how well giving Cisplatin and radiation therapy together with or without Carboplatin and Paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes.

  • Gastric Cancer EMR100070-007

    April 26, 2017

    The purpose of this study is to demonstrate superiority of treatment with Avelumab (an immunotherapy drug) versus continuation of first-line chemotherapy.

  • Gastric Cancer GS-US-296-1080

    April 11, 2017

    The primary objective of this study is to compare the efficacy of GS-5745 versus placebo in combination with modified Fluorouracil (5-FU), Leucovorin (LV), and Oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

  • Bladder Cancer CA-ALT-803-01-14

    April 11, 2017

    The purpose of this study is to evaluate the safety, identify the Maximum Tolerated Dose (MTD) of ALT-803 and determine the Recommended Dose (RD) level of ALT-803 combined with BCG in patients who have nonmuscle invasive bladder cancer. The anti-tumor activity of BCG+ALT-803 will also be assessed. In addition, the study will characterize the molecular, immunogenicity and pharmacokinetic profile of BCG+ALT-803.

  • Urinary Cancer MK-3475-361

    April 11, 2017

    The purpose of this study is to determine the efficacy and safety of Pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone. The study is for participants with advanced (infiltrating the musculature) or metastatic (the development of secondary malignant growths at a distance from a primary site of cancer) urothelial carcinoma/bladder cancer.

  • Prostate Cancer S1216

    April 11, 2017

    This trial studies androgen deprivation therapy and Orteronel to see how well it works compared to androgen deprivation therapy and Bicalutamide, in treating patients with newly diagnosed prostate cancer that has spread to other places in the body.

  • Prostate Cancer SP005

    April 11, 2017

    The purpose of this study is to determine whether DCVAC/PCa (a new Active Cellular Immunotherapy medicinal product) added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer (advanced).

  • Colorectal Cancer NRG GI-002

    April 11, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) trial studies how well Veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started, to nearby tissue or lymph nodes (locally advanced).

  • Colorectal Cancer N1048/RTOG 1271

    April 11, 2017

    The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy. The study uses a combination regimen known as FOLFOX, (the drugs 5-Fluorouracil (5-FU), Oxaliplatin and Leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.

  • Pancreatic Cancer RTOG 0848

    April 11, 2017

    This trial studies Gemcitabine Hydrochloride with or without Erlotinib Hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy, and Capecitabine or Fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Chemotherapy drugs used, such as Gemcitabine Hydrochloride, Capecitabine, and Fluorouracil, work in different ways to stop the growth of tumor cells. The drugs work either by killing the cells, stopping them from dividing, or by stopping them from spreading.

  • Breast Cancer 673-301

    April 11, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this open-label, 2:1 randomized phase III trial (Phase III trials are new treatments that have worked well in a small number of patients with this disease) is to compare the safety and efficacy of Talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer (breast cancer that has spread beyond the breast to the chest wall or the skin of the breast, or to many lymph nodes in the underarm area, or to other organs ) with germline BRCA mutations.

  • Breast Cancer CDX-011 (METRIC)

    April 11, 2017

    The main purpose of this study is to see whether CDX-011 (Glembatumumab Vedotin, a monoclonal antibody-drug conjugate. Designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents) is effective in treating patients who have advanced Triple-Negative Breast Cancer (triple negative breast cancer diagnosis means that the tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. Estrogen and progesterone receptors are receptors that may be found in breast cancer cells. Her-2 is an oncogene, a gene that has the potential to cause cancer. The study will also further characterize the safety of CDX-011 treatment in this patient population.

  • Breast Cancer ECOG E2112

    April 11, 2017

    High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Endocrine/Hormone therapy using Exemestane may fight breast cancer by lowering the amount of estrogen the body makes or interferes with the effects. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether Exemestane is more effective with or without Entinostat in treating breast cancer.

  • Breast Cancer BR003

    April 11, 2017

    Estrogen receptors and progesterone receptors are receptors that may be found in breast cancer cells. Drugs used in chemotherapy, such as Doxorubicin Hydrochloride, Cyclophosphamide, Paclitaxel, and Carboplatin, work in different ways to stop the growth of tumor cells. They work either by killing the cells, stopping cells from dividing, or by stopping cells from spreading. It is not yet known whether Doxorubicin Hydrochloride and Cyclophosphamide is more effective when followed by Paclitaxel alone or Paclitaxel and Carboplatin in treating triple-negative breast cancer.

  • Breast Cancer SWOG S1207

    April 11, 2017

    High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Hormone therapy using certain treatments may fight breast cancer, by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without Everolimus in treating breast cancer.

  • Breast Cancer B-51

    April 10, 2017

    This trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have already undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

  • Breast Cancer 16-073 PALLAS

    February 08, 2017

    A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

  • Gynecologic Cancer (Negative Pressure Wound Therapy in Post-Operative Incision Management) 15-309

    February 08, 2017

    The purpose of this study is to compare any good and bad effects of using the Prevena Incision Management System to using the usual standard dry gauze approach. The Prevena Incision Management System is a type of Negative Pressure Wound Therapy (NPWT). NPWT is a portable vacuum device made of a sponge-like foam that is applied over your incision to help draw fluid and debris out after surgery.

  • Gynecologic Cancer (HIPEC) 12-275

    January 03, 2017

    This clinical trial aims to determine the most effective method for fighting gynecologic cancer. Patients who have had a first recurrence of ovarian, fallopian tube, or primary peritoneal cancer that initially responded to platinum-based therapy and which returned more than 6 and less than 30 months after completing that therapy are eligible for this study.

  • Breast Cancer 15-307

    February 08, 2017

    Feasibility study of adjuvant enzalutamide for the treatment of early stage AR(+) triple negative breast cancer.

  • Targeted Teachable Moment Intervention Study

    January 03, 2017

    Targeted Teachable Moment Intervention Study

  • Bladder Cancer 15-291

    January 03, 2017

    Bladder cancers that invade the muscle wall of the bladder have a high risk of returning. Patients with these cancers typically have their bladders removed and are then monitored to see if the cancer comes back. In this study, researchers want to see if the drug atezolizumab can reduce the risk of cancer recurrence after bladder removal surgery for muscle-invasive bladder cancer.

  • Head/Neck Cancer 15-245

    January 03, 2017

    The treatment of head and neck cancers can sometimes leave survivors with problems such as dry mouth, difficulty swallowing, or other long-term side effects that may affect their quality of life. Researchers are interested in learning more about how survivors of head and neck cancers feel after their treatment is completed.

  • Lung Cancer CA209370

    May 09, 2017

    The purpose of this study is to determine whether Nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

  • Lung Cancer GO29537

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, multicenter, open-label study which is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with Carboplatin + Nab-Paclitaxel compared with treatment with Carboplatin + Nab-Paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

  • Lung Cancer GO29527

    May 09, 2017

    This study is for participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC). Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, global, multicenter, open-label, study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of Atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC).

  • Lung Cancer RTOG-1306

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.

  • Lung Cancer SWOG-1400

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this screening and multi-sub-study phase II/III trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

  • Lung Cancer 20070782

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this double-blind, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV.

  • Lung Cancer B7391003

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this multinational, double-blind, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of Bevacizumab-Pfizer plus Paclitaxel and Carboplatin versus Bevacizumab-EU plus Paclitaxel and Carboplatin in first-line treatment for patients with advanced non-squamous NSCLC.

  • Localized Spine Metastasis 0631

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this phase II/III trial studying how well image-guided radiosurgery or stereotactic body radiation therapy works and compares it to external-beam radiation therapy in treating patients with localized spine metastasis.

  • Castration-Resistant Prostate Cancer (Trumpet-ONC-MA-1004)

    May 09, 2017

    The purpose of this study is to describe patterns of care in CRPC (Castration-Resistant Prostate Cancer) patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

  • Venous Thromboembolism (VTE) 39039039STM4001 (BAY 59-7939)

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this multicenter, double-blind, placebo-controlled, parallel-group, superiority study comparing the efficacy and safety of Rivaroxaban with placebo for primary prophylaxis of venous thromboembolism (VTE) in ambulatory adult participants, with various cancer types who are scheduled to initiate systemic cancer therapy.

  • Solid Tumors/Lymphomas

    May 09, 2017

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

  • Metastatic/Locally Advanced Solid Tumors EMR200647-001

    May 09, 2017

    The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks in patients with metastatic or locally advanced solid tumors.

  • Bio Specimens (GRAIL)

    May 09, 2017

    This is a prospective, multi-center, observational study with collection of de-identified bio specimens and clinical data from at least 10,000 participants from clinical networks in the United States.


Cancer Clinical Research Office - Open Studies Update

View the latest open studies being conducted by the Cancer Clinical Research Office.

Click Here to View


ClinicalTrials.gov

View research studies on clinicaltrials.gov that are currently recruiting volunteers to participate.

Click Here to View